AbbVie Inc. Market Performance Summary for January 13, 2026
Current Stock Data
- Current Price: $220.04
- Previous Close: $220.08
- Change: -$0.04
- Percentage Change: -0.02%
- Opening Price: $221.19
- High Price: $222.49
- Low Price: $218.39
- Volume: 904,750 shares (10-day average: 5.91 million shares)
- Market Capitalization: $388.895 billion
- Dividend Yield: 3.14%
- 52-Week Range: $164.39 - $244.81
Market Overview
On January 13, 2026, AbbVie Inc. (NYSE: ABBV) experienced a slight decline in its stock price, closing at $220.04, down from the previous close of $220.08. The trading volume for the day was recorded at 904,750 shares, significantly lower than the 10-day average of 5.91 million shares, indicating reduced trading activity. The stock opened at $221.19, reached a high of $222.49, and dipped to a low of $218.39 during the trading session.
Recent Developments
- Completion of Bipolar Depression Trial: AbbVie announced the completion of its clinical trial for ABBV-932, a treatment for bipolar depression. This milestone has generated investor interest regarding the implications for future product development and potential market entry. The completion of clinical trials often leads to speculation about subsequent phases, regulatory approvals, and market strategies.
- Licensing Agreement with RemeGen: AbbVie has entered into an exclusive licensing agreement with RemeGen for the development of RC148, a promising therapeutic candidate. Such agreements can enhance AbbVie's portfolio and provide additional revenue streams, which are crucial for sustaining growth in the competitive biopharmaceutical market.
- Acquisition of Manufacturing Facility: AbbVie is set to acquire a manufacturing facility in Arizona from West Pharmaceutical for $112.5 million. This acquisition is part of AbbVie's strategy to bolster its production capabilities and expand its operational footprint. The associated intellectual property from this deal may also provide AbbVie with a competitive edge in manufacturing processes.
- Sale of SmartDose Rights: In a related transaction, West Pharmaceutical will sell the rights to its SmartDose 3.5mL product to AbbVie. This acquisition is expected to enhance AbbVie's product offerings in drug delivery systems, aligning with its commitment to innovative solutions in patient care.
Market Context
AbbVie operates in the biopharmaceutical sector, focusing on the research, development, and commercialization of various therapeutic products. The company has established a strong presence in immunology and oncology, which are critical areas of growth in the pharmaceutical industry. The current market capitalization of AbbVie stands at approximately $388.895 billion, positioning it as a significant player in the market.
Upcoming Events
- Earnings Report: AbbVie is scheduled to report its earnings on February 4, 2026. Earnings reports are critical as they provide insights into the company's financial health and operational performance.
- Ex-Dividend Date: The ex-dividend date is set for January 16, 2026, with a declared dividend amount of $1.73. The dividend yield of 3.14% is attractive to income-focused investors and may provide support for the stock price.
Conclusion
The slight decline in AbbVie's stock price on January 13, 2026, reflects a period of stability amidst significant developments, including the completion of clinical trials, strategic acquisitions, and licensing agreements. These factors may position AbbVie favorably for future growth, although the reduced trading volume suggests a cautious approach among investors. The upcoming earnings report and dividend declaration will be critical in shaping investor sentiment and stock performance in the near term.
Explore more exclusive insights at nextfin.ai.